Diner Cut Capsule 20mg (Fluoxetine Hydrochloride)

Adult dosage

Adults 1. Depression 1) Initial treatment: As the initial dose, administer 20mg of fluoxetine hydrochloride orally once daily in the morning. In controlled clinical trials, doses of 20～80mg per day were administered. If no improvement is observed, a dose increase may be considered after several weeks. Doses exceeding 20mg per day should be administered in 2 divided doses (morning and noon), and the maximum dose of 80mg per day should not be exceeded. The onset of an adequate antidepressant effect may be delayed until 4 weeks or longer after the start of treatment. 2) Maintenance/continuation/extended treatment: There are no definitive data on how long a patient should be treated with this medicine, but psychopharmacologists recognize that acute symptoms of depression require medication for several months or longer. It is not known whether the amount of antidepressant needed to relieve symptoms is the same as that needed to maintain or sustain stability. 2. Bulimia nervosa Administer 60mg of this medicine per day. The daily dose should not exceed 80mg. Measure electrolyte concentrations before starting treatment. 3. Obsessive-compulsive disorder Administer 20～60mg of this medicine per day. The daily dose should not exceed 80mg. 4. Premenstrual dysphoric disorder Administer 20mg of this medicine per day. Reassess the need for continued treatment after 6 months of therapy. Patients with renal and/or hepatic impairment, patients taking multiple medications, elderly patients, and patients with concomitant illnesses: Administer a lower dose or reduce the frequency of administration. Adjust the dose appropriately according to age and symptoms. Switching from MAO inhibitors used to treat psychiatric disorders When discontinuing an MAO inhibitor used to treat psychiatric disorders and starting treatment with this medicine, allow an interval of at least 14 days. Conversely, when starting an MAO inhibitor to treat psychiatric disorders, at least 5 weeks must have elapsed after discontinuing this medicine. Other MAO inhibitors, such as linezolid or methylene blue Patients receiving linezolid or intravenous methylene blue should not start treatment with this medicine because of the increased risk of serotonin syndrome. For patients requiring more urgent treatment of a psychiatric condition, including hospitalization or other interventions, treatment should be considered. It may be necessary to urgently administer linezolid or intravenous methylene blue to a patient already receiving this medicine. If there is no alternative to linezolid or intravenous methylene blue and, for a particular patient, the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome, this medicine may be stopped immediately and linezolid or intravenous methylene blue administered. Monitor the patient for symptoms of serotonin syndrome for 5 weeks after administration of linezolid or intravenous methylene blue, or until 24 hours after the last dose, whichever occurs first. Treatment with this medicine may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with administration of methylene blue by non-intravenous routes (oral tablets or local injection), or with intravenous injection of this medicine at 1mg/kg or less, is unclear. Nevertheless, clinicians should be aware of the possibility of emergency symptoms of serotonin syndrome with these uses.

This medication may increase the risk of suicidal thoughts or behaviors in children, adolescents, and young adults with major depression or other psychiatric disorders, so a physician should carefully evaluate when prescribing to patients in this age group. This medication should not be administered to certain patients, such as those with allergies to this drug or its excipients, severe renal impairment, and patients taking MAO inhibitors. Patients with a history of seizures should use this medication cautiously as it may increase the risk of seizures, and close monitoring is required for patients at risk of suicide during the initial treatment phase. Patients with cardiovascular disease or impaired liver or kidney function need dose adjustments or special monitoring. Diabetic patients should periodically check blood glucose levels as this drug may affect blood sugar control. This medication can dilate pupils, so patients at risk of glaucoma or elevated intraocular pressure should exercise caution. Common side effects during treatment may include headache, nausea, insomnia, fatigue, and diarrhea, while severe allergic reactions or hepatitis, skin rash, etc., can occur infrequently. Upon discontinuation, withdrawal symptoms such as dizziness, sensory disorders, sleep disturbances, anxiety, nausea, tremors, and headache may occur, so gradual tapering of the dose is recommended. This medication can cause serious side effects such as serotonin syndrome when taken with other serotonergic drugs, so special caution is needed when co-administering. Alcohol consumption is not recommended, and it is safest to avoid drinking while taking this medication. During pregnancy, a careful evaluation of the risks to the fetus and the benefits of this medication must be considered, and during breastfeeding, consideration should be given to the possibility of discontinuing breastfeeding due to excretion into breast milk. The safety and efficacy in children and adolescents have not been established, so it’s preferable to avoid administration. Elderly patients may have an increased risk of adverse effects based on other conditions or medications, so caution is necessary. In the case of overdose, serious symptoms such as nausea, seizures, and cardiac arrhythmias may occur, requiring immediate medical assistance. Store the medication in a tightly sealed container, out of the reach of children, and do not transfer it to another container. Caution is advised when driving or operating dangerous machinery as this medication may impair judgment or motor function post-administration. Patients with a history of substance abuse should discuss the potential for abuse of this medication with their healthcare provider.

Headache, nausea, insomnia, fatigue, diarrhea, anaphylactic reaction, serum sickness, abnormal secretion of antidiuretic hormone, decreased appetite, hyponatremia, anxiety, nervousness, restlessness, tension, decreased libido, sleep disorders, abnormal dreams, depersonalization, elevated mood, euphoric mood, thought disorder, abnormal libido, bruxism, hypomania, mania, hallucinations, agitation, panic attacks, suicidal impulses, behavior changes, confusion, attention deficit, dizziness, taste disturbances, hypersomnia, drowsiness, tremors, psychomotor agitation, movement disorders, ataxia, balance disorders, myoclonus, convulsions, inability to sit still, Buccoglossal syndrome, serotonin syndrome, memory impairment, blurred vision, pupil dilation, palpitations, ventricular arrhythmias, QT prolongation, flushing, hypotension, vasculitis, vasodilation, yawning, dyspnea, pharyngitis, pulmonary-related inflammation and fibrosis, epistaxis, vomiting, dyspepsia, dry mouth, dysphagia, esophageal pain, gastrointestinal bleeding, specific hepatitis, rash, hives, itching, hyperhidrosis, hair loss, increased bruising, cold sweat, angioedema, petechiae, photosensitivity, purpura, erythema multiforme, arthralgia, myopathy, myalgia, polyuria, dysuria, urinary retention, urination disorders, gynecological bleeding, erectile dysfunction, ejaculation disorders, sexual dysfunction, galactorrhea, hyperprolactinemia, priapism, anxious mood, chills, lethargy, abnormal mood, feeling cold, feeling hot, mucosal bleeding, weight loss, abnormal liver function tests, suicidal thoughts, suicidal behavior, fractures, withdrawal symptoms (dizziness, sensory disturbances, sleep disturbances, weakness, agitation, anxiety, nausea, vomiting, tremors, headache), anaphylactoid reaction, progressive systemic reactions, severe skin, kidney, liver, or pulmonary-related reactions, suicide-related behaviors, growth delay, delayed puberty, Stevens-Johnson syndrome, changes in platelet function, bleeding, akathisia, serotonin syndrome, aplastic anemia, atrial fibrillation, cataracts, cerebrovascular accidents, cholestatic jaundice, dyskinesia, eosinophilic pneumonia, epithelial necrosis, erythema multiforme, nodular erythema, exfoliative dermatitis, gynecomastia, cardiac arrest, liver failure, hyperprolactinemia, hypoglycemia, immune-related hemolytic anemia, renal failure, exacerbation of movement disorders, optic neuritis, pancreatitis, pancytopenia, pulmonary embolism, pulmonary hypertension, thrombocytopenia, thrombocytopenic purpura, ventricular tachycardia, vaginal bleeding, aggressive behavior

This medication should be stored in a tightly sealed container to protect it from air and moisture. It should be stored at room temperature between 1 degrees Celsius and 30 degrees Celsius.

Appearance

A hard capsule with a green upper part and a yellowish lower part filled with a white to grayish powder.

Package unit

30 capsules/bottle, 300 capsules/bottle